Ann: Race starts preclinical breast cancer study for Bisantrene, page-57

First 57 Last

Share
Profile

Follow
IndexInvestor

8,625 Posts.

1425

25/08/21

01:38

Post #: 55543532
Share

Originally posted by Mason14: ↑

There can be a little more added to this that @IndexInvestor should really have generously explained to you.

Zantrene was shown to be significantly more potent (between 2x and 5x) than other anthracyclines in MCF-7 breast cancer cells resistant to a number of different SoC drugs.

The MCF-7 cells used in this trial have been previously identified as breast cancer cells that have upregulated FTO (1,2).

MCF-7 cells that had been pre-treated with Doxorubicin lead to an upregulation of FTO (3). I speculate that pretreatment of the SoC drugs in the MCF-7 breast cancer cells may have upregulated cellular FTO, which is why Bisantrene was sensitive and the other anthracyclines were not (the upregulated FTO led to drug resistance).

Based on this data, I am very confident that the results observed in the most recently announced preclinical breast cancer results is a result of Zantrene inhibtiing FTO in these cell lines. An interesting thought provoker is the magnitude or scale of FTO upregulation being central to anti-cancer therapy resistance.

The preclinical breast cancer program is continuing, which I believe will include mouse models and drug combinations with a multi-billion dollar breast cancer drug like a HER-2 monoclonal (I think likely), or maybe even something like Trodelvy. There might be other possible and more likely drug combinations, but it's a bit late for me in Perth and that's all I can come up with.

1 https://www.spandidos-publications.com/10.3892/ol.2017.6038
2 https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-019-1004-4
3 https://www.tandfonline.com/doi/full/10.1080/21655979.2021.1924544

Expand

I hereby assure @Mason14 and all HC posters that the reason that I didn't post anything about MCF-7 lines and what the expanded scope of this preclinical may plausibly be is not out of any lack of generosity, but simply because I'm incapable of having written any part of it.

And it will take me some time to attempt to absorb what Mason has generously provided. Not now; it's a bit late for me in Sydney.

Buy, Held

Last edited by IndexInvestor: 25/08/21
33 Upvote

0 Great analysis

Reply

Top Stories

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

What's causing the cost-of-living crisis, and how to navigate it

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

M4M

Macro, Norden set up transport solutions initiative for West Pilbara